Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,213
  • Shares Outstanding, K 39,955
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,020 K
  • EBIT $ -112 M
  • EBITDA $ -112 M
  • 60-Month Beta 2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.93

Options Overview Details

View History
  • Implied Volatility 425.82% ( -21.53%)
  • Historical Volatility 74.64%
  • IV Percentile 99%
  • IV Rank 94.99%
  • IV High 447.35% on 12/19/24
  • IV Low 17.80% on 07/08/24
  • Put/Call Vol Ratio 0.56
  • Today's Volume 137
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 8,545
  • Open Int (30-Day) 8,342

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.78
  • Number of Estimates 7
  • High Estimate -0.62
  • Low Estimate -0.91
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +22.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.90 +6.67%
on 12/20/24
6.11 -31.91%
on 11/25/24
-0.80 (-16.13%)
since 11/20/24
3-Month
3.90 +6.67%
on 12/20/24
8.01 -48.06%
on 09/23/24
-3.70 (-47.07%)
since 09/20/24
52-Week
3.90 +6.67%
on 12/20/24
15.05 -72.36%
on 03/28/24
-0.78 (-15.79%)
since 12/20/23

Most Recent Stories

More News
Insider Sale: President and CEO of $SLDB (SLDB) Sells 11,114 Shares

Alexander Cumbo, the President and CEO of $SLDB ($SLDB), sold 11,114 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 22.4%...

SLDB : 4.16 (+3.74%)
Insider Sale: Chief Technology Officer of $SLDB (SLDB) Sells 2,777 Shares

Paul Herzich, the Chief Technology Officer of $SLDB ($SLDB), sold 2,777 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 18.6%...

SLDB : 4.16 (+3.74%)
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies

SLDB : 4.16 (+3.74%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLDB : 4.16 (+3.74%)
Solid Biosciences to Participate at Upcoming Investor Conferences

SLDB : 4.16 (+3.74%)
Solid Biosciences to Present at the Jefferies London Healthcare Conference

SLDB : 4.16 (+3.74%)
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

SLDB : 4.16 (+3.74%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLDB : 4.16 (+3.74%)
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium

SLDB : 4.16 (+3.74%)
Are Gene Therapy Stocks The Market's Next Big Winners?

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

SRPT : 118.97 (-0.42%)
BMRN : 65.66 (+1.02%)
BIIB : 146.47 (-0.62%)
CRSP : 40.72 (+0.83%)
EDIT : 1.3100 (-2.24%)
NTLA : 12.18 (+0.83%)
NVS : 97.11 (+0.35%)
ORTX : 16.70 (+0.30%)
REGN : 701.85 (-0.90%)
SLDB : 4.16 (+3.74%)
BLUE : 8.50 (-7.91%)

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

3rd Resistance Point 4.79
2nd Resistance Point 4.56
1st Resistance Point 4.36
Last Price 4.16
1st Support Level 3.93
2nd Support Level 3.70
3rd Support Level 3.50

See More

52-Week High 15.05
Fibonacci 61.8% 10.79
Fibonacci 50% 9.48
Fibonacci 38.2% 8.16
Last Price 4.16
52-Week Low 3.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar